Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Benefits Of Targeting Both Pericytes And Endothelial Cells In The Tumor Vasculature With Kinase Inhibitors.
G. Bergers, S. Song, Nicole Meyer-Morse, E. Bergsland, D. Hanahan
Published 2003 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Functions of receptor tyrosine kinases implicated in angiogenesis were pharmacologically impaired in a mouse model of pancreatic islet cancer. An inhibitor targeting VEGFRs in endothelial cells (SU5416) is effective against early-stage angiogenic lesions, but not large, well-vascularized tumors. In contrast, a kinase inhibitor incorporating selectivity for PDGFRs (SU6668) is shown to block further growth of end-stage tumors, eliciting detachment of pericytes and disruption of tumor vascularity. Importantly, PDGFRs were expressed only in perivascular cells of this tumor type, suggesting that PDGFR(+) pericytes in tumors present a complimentary target to endothelial cells for efficacious antiangiogenic therapy. Therapeutic regimes combining the two kinase inhibitors (SU5416 and SU6668) were more efficacious against all stages of islet carcinogenesis than either single agent. Combination of the VEGFR inhibitor with another distinctive kinase inhibitor targeting PDGFR activity (Gleevec) was also able to regress late-stage tumors. Thus, combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor.
This paper references
The Hallmarks of Cancer
D. Hanahan (2000)
STI571 (Gleevec) as a paradigm for cancer therapy.
B. Druker (2002)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G. Bergers (2000)
Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis
M. Hellström (2001)
Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis.
G. Bergers (1998)
In vivo intracellular signaling as a marker of antiangiogenic activity.
C. Solórzano (2001)
A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.
L. Benjamin (1998)
Control of angiogenesis by the pericyte: molecular mechanisms and significance.
K. Hirschi (1997)
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
T. Fong (1999)
Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
K. Pietras (2001)
Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
P. Vajkoczy (2000)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.
M. Inoue (2002)
Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects
M. Sternlicht (2000)
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
A. Laird (2003)
The versatility of microvascular pericytes: from mesenchyme to smooth muscle?
V. Nehls (2004)
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
G. Bergers (2002)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
D. Hanahan (1996)
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
R. Shaheen (2001)
D. Fabbro (2001)
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
L. Coussens (2002)
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
P. Vajkoczy (1999)
Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.
M. Hellström (1999)
Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models.
D. Hanahan (1996)
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.
P. Lindahl (1997)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G. Klement (2000)
Angiogenesis and prostate cancer: identification of a molecular progression switch.
W. Huss (2001)
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival
N. Reinmuth (2001)
Pericytes in the microvasculature.
K. Hirschi (1996)
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.
S. Morikawa (2002)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
G. Klement (2000)
Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma.
S. Parangi (1995)
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
A. Dash (2002)
J. Folkman (1985)
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
N. Ferrara (2002)
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
G. Bergers (1999)
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
T. Browder (2000)
Clinical translation of angiogenesis inhibitors
R. Kerbel (2002)
SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
A. Laird (2002)
Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
D. Hanahan (1985)
Bcr-Abl inhibition as a modality of CML therapeutics.
E. Buchdunger (2001)
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
A. Laird (2000)
Fibroblast growth factors are required for efficient tumor angiogenesis.
A. Compagni (2000)
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis.
T. Lopez (2002)
Induction of angiogenesis during the transition from hyperplasia to neoplasia
J. Folkman (1989)
This paper is referenced by
Translational studies in urologic oncology Clinical implications of hypoxia inducible factor in renal cell carcinoma
Marc C Smaldone (2009)
The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
A. Agapidou (2016)
Adaptation to antiangiogenic therapy in neurological tumors
P. Flanigan (2015)
Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
Caroline Berenguer-Daizé (2013)
Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways
R. Grépin (2014)
Overcoming VEGF resistance in renal cancer: biologic and therapeutic implications
S. Sadeghi (2012)
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Vesselina G. Cooke (2012)
Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective
M. Singh (2006)
Inhibition of Reactive Gliosis Prevents Neovascular Growth in the Mouse Model of Oxygen-Induced Retinopathy
M. Deniro (2011)
Prodrug Gene Therapy for Cancer Mediated by Mesenchymal Stem/Stromal Cells Engineered to Express Yeast Cytosinedeaminase::Uracilphos phoribosyltransferase
C. Altaner (2015)
Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran
S. Shamsdin (2019)
Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
R. Bagley (2006)
Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.
Masao Furuhashi (2004)
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.
Jason A. Hoffman (2003)
Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.
J. Sosman (2003)
Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis
I. Albrecht (2010)
Tumor Blood Vessels and Tumor Endothelial Cells
D. Ribatti (2016)
Targeting the PDGF signaling pathway in tumor
C. Heldin (2013)
Angiogenesis and its modulation in the pathophysiology and treatment of endometrial carcinoma
Craig A Mayr (2011)
[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
P. Xing (2016)
Preadministration of High-Dose Salicylates, Suppressors of NF-κB Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy
M. Mccarty (2006)
Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years
Leigh H Spielberg (2009)
Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis
A. Östman (2008)
Cold shock domain protein A represses angiogenesis and lymphangiogenesis via inhibition of serum response element
Y. Saitō (2008)
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
L. Saltz (2007)
Targeting the tumor microenvironment (Stroma) for treatment of metastasis
I. Fidler (2008)
Endothelium-microenvironment interactions in the developing embryo and in the adult.
K. Red-Horse (2007)
Molecular targets for retinal vascular diseases
P. Campochiaro (2007)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
D. Reardon (2005)
The merits of vascular targeting for gynecologic malignancies
A. Kamat (2005)
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma.
D. Ribatti (2010)
Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis.
C. Fischer (2006)See more